Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/178533
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Robak, Tadeusz | - |
dc.contributor.author | Huang, Huiqiang | - |
dc.contributor.author | Jin, Jie | - |
dc.contributor.author | Zhu, Jun | - |
dc.contributor.author | Liu, Ting | - |
dc.contributor.author | Samoilova, Olga | - |
dc.contributor.author | Pylypenko, Halyna | - |
dc.contributor.author | Verhoef, Gregor | - |
dc.contributor.author | Siritanaratkul, Noppadol | - |
dc.contributor.author | Osmanov, Evgenii | - |
dc.contributor.author | Alexeeva, Julia | - |
dc.contributor.author | Pereira, Juliana | - |
dc.contributor.author | Drach, Johannes | - |
dc.contributor.author | Mayer, Jiří | - |
dc.contributor.author | Hong, Xiaonan | - |
dc.contributor.author | Okamoto, Rumiko | - |
dc.contributor.author | Pei, Lixia | - |
dc.contributor.author | Rooney, Brendan | - |
dc.contributor.author | Van de Velde, Helgi | - |
dc.contributor.author | Cavalli, Franco | - |
dc.contributor.author | González Barca, Eva | - |
dc.contributor.author | LYM-3002 Investigators | - |
dc.date.accessioned | 2021-06-17T14:47:47Z | - |
dc.date.available | 2021-06-17T14:47:47Z | - |
dc.date.issued | 2015-03-05 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.uri | http://hdl.handle.net/2445/178533 | - |
dc.description.abstract | Background: the proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma. Methods: in this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11). The primary end point was progression-free survival. Results: after a median follow-up of 40 months, median progression-free survival (according to independent radiologic review) was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group (hazard ratio favoring the VR-CAP group, 0.63; P<0.001), a relative improvement of 59%. On the basis of investigator assessment, the median durations of progression-free survival were 16.1 months and 30.7 months, respectively (hazard ratio, 0.51; P<0.001), a relative improvement of 96%. Secondary end points were consistently improved in the VR-CAP group, including the complete response rate (42% vs. 53%), the median duration of complete response (18.0 months vs. 42.1 months), the median treatment-free interval (20.5 months vs. 40.6 months), and the 4-year overall survival rate (54% vs. 64%). Rates of neutropenia and thrombocytopenia were higher in the VR-CAP group. Conclusions: VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hematologic toxicity. (Funded by Janssen Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials.gov number, NCT00722137). | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Massachusetts Medical Society | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa1412096 | - |
dc.relation.ispartof | New England Journal of Medicine, 2015, vol. 372, num. 10, p. 944-953 | - |
dc.relation.uri | https://doi.org/10.1056/NEJMoa1412096 | - |
dc.rights | (c) Massachusetts Medical Society, 2015 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Medicaments antineoplàstics | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Ús terapèutic | - |
dc.subject.other | Antineoplastic agents | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | Therapeutic use | - |
dc.title | Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 679862 | - |
dc.date.updated | 2021-06-17T14:47:47Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 25738670 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
679862.pdf | 391.52 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.